Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

4D Molecular Therapeutics Q2 EPS $(0.98) Misses $(0.85) Estimate, Sales $15.000K Miss $374.143K Estimate

Author: Benzinga Newsdesk | August 11, 2025 07:17am
4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of $(0.85) by 14.75 percent. This is a 55.56 percent decrease over losses of $(0.63) per share from the same period last year. The company reported quarterly sales of $15.000 thousand which missed the analyst consensus estimate of $374.143 thousand by 95.99 percent. This is a 200.00 percent increase over sales of $5.000 thousand the same period last year.

Posted In: FDMT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist